{
    "Trade/Device Name(s)": [
        "HemosIL D-Dimer HS 500"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K172903",
    "Predicate Device Reference 510(k) Number(s)": [
        "K090264"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "October 26, 2017",
    "Summary Letter Received Date": "October 27, 2017",
    "Submission Date": "November 17, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/fibrin degradation products assay"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "D-Dimer"
    ],
    "Specimen Type(s)": [
        "Citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family",
        "ACL TOP Family 50 Series Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Automated latex enhanced immunoassay",
        "Latex-enhanced immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Turbidimetric immunoassay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL D-Dimer HS 500 automated latex-enhanced immunoassay for quantitative D-Dimer measurement on ACL TOP analyzers",
    "Indications for Use Summary": "Automated latex enhanced immunoassay for quantitative determination of D-Dimer in citrated plasma on ACL TOP systems, used with clinical pretest probability assessment to exclude venous thromboembolism (VTE) in outpatients suspected of deep venous thrombosis and pulmonary embolism",
    "fda_folder": "Hematology"
}